Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.

Simone ClaudianiJane F ApperleyEleanor L ParkerFederica MarchesinKsenia KatsanovskajaRenuka PalanicawandarAndrew J InnesRichard S TedderMyra O McClureDragana Milojkovic

Published in: British journal of haematology (2021)

Keyphrases

sars cov
end stage renal disease
newly diagnosed
chronic kidney disease
immune response
ejection fraction
dendritic cells
bone marrow
acute myeloid leukemia
respiratory syndrome coronavirus
coronavirus disease